期刊文献+

宫颈腺癌组织ERK1/2和p16^(INK4a)及P-gp表达与耐药相关性分析 被引量:1

Expressions of ERK1/2,p16^(INK4a) and P-gp in cervical adenocarcinoma and its relation to chemoresistance
原文传递
导出
摘要 目的:探讨细胞外信号调节激酶1/2(ERK1/2)、p16INK4a及P-糖蛋白(P-gp)与宫颈腺癌耐药的关系。方法:PV9000免疫组化二步法检测化疗敏感组(14例)及耐药组(25例)宫颈腺癌活检组织中ERK1/2、p16INK4a及P-gp蛋白的表达情况,分析ERK1/2、p16INK4a及P-gp在两组的表达差异、3者的表达相关性及与宫颈腺癌患者3年生存率的关系。结果:ERK1/2在耐药组及敏感组的高表达率分别为72.0%(18/25)及35.7%(5/14),差异有统计学意义,U=96,P=0.016;P-gp在耐药组的高表达率为76.0%(19/25),显著高于敏感组的28.6%(4/14),差异有统计学意义,U=102,P=0.026;p16INK4a蛋白在耐药组及敏感组的表达差异无统计学意义,U=129,P=0.140。ERK1/2与p16INK4a的表达呈正相关,r=0.571,P<0.001;ERK1/2与P-gp的表达呈正相关,r=0.364,P=0.023;p16INK4a与P-gp的表达无明显相关性,r=0.254,P=0.132。ERK1/2高表达与低表达患者的3年生存率分别为60.9%(14/23)和93.8%(15/16),差异有统计学意义,χ2=4.723,P=0.030;而p16INK4a高表达与低表达患者的3年生存率分别为68.0%(17/25)和85.7%(12/14),差异无统计学意义,χ2=1.355,P=0.244;P-gp高表达与低表达患者的3年生存率分别为65.2%(15/23)和87.5%(14/16),差异无统计学意义,χ2=2.347,P=0.125。结论:ERK1/2和P-gp的高表达与宫颈腺癌耐药相关;ERK1/2的表达情况不仅可为宫颈腺癌化疗用药提供参考,而且可作为宫颈腺癌判断预后的指标。 OBJECTIVE:To explore relation between the expressions of extracellular signal-regulated kinase 1/2(ERK1/2),p16INK4a,P-glycoprotein(P-gp)and the chemoresistance of cervical adenocarcinoma.METHODS:PV9000immunohistochemistry was used to detect the expressions of ERK1/2,p16INK4aand P-gp in the biopsy specimens of cervical adenocarcinoma of chemosensitive group(14patients)and chemoresistant group(25patients).Expression differences of ERK1/2,p16INK4aand P-gp between the chemosensitive group and chemoresistant group and the correlation among them were analyzed.The relation between the expressions of ERK1/2,p16INK4aand P-gp and the 3-year survival rate of the patients with cervical adenocarcinoma was analyzed.RESULTS:The highly expressed rates of ERK1/2in chemoresistant group and chemosensitive group were 72.0%(18/25)and 35.7%(5/14)respectively,and there was statistical significance between them(U=96,P=0.016);the highly expressed rate of P-gp was 76.0%(19/25)in chemoresistant group which was obviously higher than that of chemosensitive group 28.6%(4/14),and this difference was statistically significant(U=102,P=0.026);while the expression differences of p16INK4abetween the chemoresistant group and chemosensitive group were not statistically significant(U =129,P=0.140).The expression of ERK 1/2was positively correlated with that of p16INk4a(r=0.571,P0.001),and the expression of ERK1/2was positively correlated with that of P-gp(r=0.364,P=0.023),while there was no obvious correlation between the expression of p16INK4aand the expression of P-gp(r=0.254,P=0.132).The 3-year survival rates of ERK1/2highly expressed patients and lowly expressed patients were60.9%(14/23)and 93.8%(15/16)respectively,and there was statistically significant between them(χ2=4.723,P=0.030);while the 3-year survival rates of p16INK4ahighly expressed patients and lowly expressed patients were 68.0%(17/25)and 85.7%(12/14),there was no statistical significance between them(χ2=1.355,P=0.244);the 3-year survival rates of P-gp highly expressed patients and lowly expressed patients were 65.2%(15/23)and 87.5%(14/16),there was no statistical significance between them(χ2=2.347,P=0.125).CONCLUSIONS:The high expression of ERK1/2and P-gp associates with the chemoresistance of cervical adenocarcinoma.ERK1/2may be used as a predictor for the selection of chemotherapy regimen and the prognosis of cervical cancer adenocarcinoma.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2013年第19期1508-1512,共5页 Chinese Journal of Cancer Prevention and Treatment
基金 国家自然科学基金(81260383)
关键词 宫颈肿瘤 ERK1 2蛋白 P16INK4A蛋白 P-糖蛋白 抗药性 多药 cervical neoplasis ERK1/2protein p16INK4aprotein P-glycoprotein drug resistance multiple
  • 相关文献

参考文献5

二级参考文献16

共引文献46

同被引文献16

  • 1姚凡,金锋,樊华,路平,陈波,徐惠绵,王舒宝.ERK信号传导抑制逆转大肠癌多药耐药的研究[J].中国肿瘤临床,2005,32(5):290-291. 被引量:4
  • 2王赛特.大肠癌已成为第二大常见肿瘤[N].解放日报,2008-4-2(213).
  • 3GILLET J P,GOTTESMAN M M.Mechanisms of multidrug resistance in cancer[J].Methods Mol Biol,2010,596:47-76.
  • 4OCHI N,TAKIGAWA N,HARADA D,et al.Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer[J].Experimental Cell Research,2014,322:168-177.
  • 5FAN D P,ZHANG Y M,HU X C,et al.Activation of AKT/ERK confers non-small cell lung cancer cells resistance to vinorelbine[J].Int J Clin Exp Pathol,2014,7:134-143.
  • 6BUONATO J M,LAZZARA M J:ERK1/2Blockade Prevents Epithelial-Mesenchymal Transition in Lung Cancer Cells and Promotes Their Sensitivity to EGFR Inhibition[J].Cancer Research,2013,74:309-319.
  • 7ZHAO B X,SUN Y B,WANG S Q,et al.Grape Seed Procyanidin Reversal of P-glycoprotein Associated Multi-Drug Resistance via Down-regulation of NF-κB and MAPK/ERK Mediated YB-1Activity in A2780/T Cells[J].PLoS One,2013,8:e71071.
  • 8AHMEDIN J D,FREDDIE BRAY,MELISSA M,et al.Global Cancer Statistics[J].Ca Cancer J Clin,2011,61:69-90.
  • 9WOODLAND C,KOREN G,WAINER I W,et al.Vcrapamil mctabolitcs:potcntial P-glycoprotein-mediated multidrug resistance reversal agents[J].Can J Physiol Pharmacol,2003,81:800-805.
  • 10TAKARA K,SAKAEDA T,OKUMURA K.An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy[J].Curr Pharm Des,2006,12:273-286.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部